It’s been claimed that thousands of men with advanced prostate cancer could be denied a new drug following guidance from NICE. NICE initially recommended for NHS funding last October but have reversed this decision. NICE have justified the decision claiming there is a lack of evidence. Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months. However, it will be banned for patients in England previously treated with abiraterone, another new drug currently used in advanced cases.
Fear over NICE guidance on prostate cancer drug
Deprecated: ltrim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/whitehouseconsulting_584/public/wp-includes/formatting.php on line 4558
28 January 2014
5 MINS 30 SECS
If you would like to understand what these developments mean, please get in touch with our specialist team.
Related
